Cancers
An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance.
Elsa Irving, Alaide Morcavallo, Jekaterina Vohhodina-Tretjakova, Paul W G Wijnhoven, Anna L Beckett, Michael P Jacques, Rachel S Evans, Jennifer I Moss, Anna D Staniszewska, Josep V Forment
Published: 202610.3390/cancers18020309
Abstract
BACKGROUND: Poly(ADP-ribose) polymerase inhibitors (PARPi) have transformed cancer therapy for patients harbouring homologous recombination repair (HRR) deficiencies, notably BRCA1/2 mutations. However, resistance to PARPi remains a clinical challeng…
Preview only. Read the full abstract at the source